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Abstract: BACKGROUND Contemporary ICD programming involving delayed high-rate detection and
use of SVT discriminators has significantly reduced the rate of inappropriate shocks. The extent to
which SVT algorithms alone reduce inappropriate therapies is poorly understood. METHODS AND
RESULTS PainFree SST enrolled 2,770 patients with a single or dual-chamber ICD or cardiac resyn-
chronization defibrillator. Patients were followed for 22±9 months with SVT discriminators on in 96% of
patients. Sustained ventricular tachyarrhythmias and SVT episodes were adjudicated by an independent
physician committee. For this analysis, all episodes were subjected to post-processing computer simula-
tion with SVT discriminators off with and without delayed high-rate detection criteria (VF zone only,
30/40@320ms). There were 3,282 adjudicated SVT episodes of which 115 resulted in an ICD shock and
113 received only ATP (2-year inappropriate shock and therapy rates of 3.1% and 4.1%). Therapy was
appropriately withheld for the remaining 3,054 SVT episodes. With both SVT discriminators and delayed
high-rate detection simulated off, the 2-year inappropriate therapy rate would have been 22.9% (Hazard
Ratio [HR]=6.24, 95% confidence interval [CI]: 5.20-7.49). With SVT discriminators simulated off and
delayed high-rate detection simulated on in all patients, the 2-year rate would have been 6.4% (HR=1.63,
CI: 1.44-1.85). CONCLUSIONS Use of SVT discriminators has a significant role in reducing the rate
of inappropriate ICD therapy even in the setting of delayed high-rate detection settings. Deactivating
SVT discriminators would have resulted in an overall increase in the inappropriate ICD therapy rate by
63% and 524% with and without delayed high-rate detection programming, respectively. This article is
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Abstract 
Background: Contemporary ICD programming involving delayed high-rate detection 
and use of SVT discriminators has significantly reduced the rate of inappropriate shocks. 
The extent to which SVT algorithms alone reduce inappropriate therapies is poorly 
understood.  
Methods and Results: PainFree SST enrolled 2,770 patients with a single or dual-
chamber ICD or cardiac resynchronization defibrillator. Patients were followed for 22±9 
months with SVT discriminators on in 96% of patients. Sustained ventricular 
tachyarrhythmias and SVT episodes were adjudicated by an independent physician 
committee. For this analysis, all episodes were subjected to post-processing computer 
simulation with SVT discriminators off with and without delayed high-rate detection 
criteria (VF zone only, 30/40@320ms). There were 3,282 adjudicated SVT episodes of 
which 115 resulted in an ICD shock and 113 received only ATP (2-year inappropriate 
shock and therapy rates of 3.1% and 4.1%). Therapy was appropriately withheld for the 
remaining 3,054 SVT episodes. With both SVT discriminators and delayed high-rate 
 














detection simulated off, the 2-year inappropriate therapy rate would have been 22.9% 
(Hazard Ratio [HR]=6.24, 95% confidence interval [CI]: 5.20-7.49). With SVT 
discriminators simulated off and delayed high-rate detection simulated on in all patients, 
the 2-year rate would have been 6.4% (HR=1.63, CI: 1.44-1.85). 
Conclusions: Use of SVT discriminators has a significant role in reducing the rate of 
inappropriate ICD therapy even in the setting of delayed high-rate detection settings. 
Deactivating SVT discriminators would have resulted in an overall increase in the 
inappropriate ICD therapy rate by 63% and 524% with and without delayed high-rate 
detection programming, respectively. 
Clinical Trial Registration: URL: http://clinicaltrials.gov Unique Identifier: 
NCT00982397 
Keywords: Implantable cardioverter defibrillator, cardiac resynchronization therapy, 
heart failure, atrial fibrillation, inappropriate shock 
Introduction 
Early implantable cardioverter defibrillator (ICD) programming was designed to 
rapidly detect and treat ventricular arrhythmias.
1
 Unfortunately, this resulted in therapies 
that were either inappropriate or unnecessary. In particular, among patients receiving 
ICDs for primary prevention of sudden cardiac death, almost 40% of the therapies 
delivered were deemed inappropriate or unnecessary. Recent advancements in our 
understanding of arrhythmia outcomes and improvements in ICD diagnostics and 
algorithms have placed greater focus on treating longer, faster ventricular arrhythmias 




















 use, and/or the application of supraventricular tachycardia 
(SVT) discriminators. While the programming options are similar across the different 
device manufacturers, recent Heart Rhythm Society (HRS) guidance have cautioned 
against generalizing learnings from one manufacturer’s device platform to others because 
operation details differ.
6
 Hence, there is a need to better understand patient outcomes 
from these interventions that are contemporary and device manufacturer-specific.  
The PainFree SST trial was a prospectively enrolling study that included primary 
and secondary prevention Medtronic ICD recipients to assess the effectiveness of 
SmartShock Technology™ (SST), a suite of 6 proprietary SVT and non-arrhythmia 
discriminators (for rejection of lead noise, T wave oversensing, and lead integrity alert) 
aimed at reducing overall inappropriate ICD therapies
7, 8
 in the setting of modern day use 
of delayed high-rate detection programming and ATP. This study demonstrated an 
overall inappropriate ICD shock rate of 1.5% at 12 months in dual and triple chamber 
ICDs and 2.5% in single chamber ICDs, the lowest reported in any large prospective 
trial.
8, 9
 Whether the primary benefit was derived from delayed high-rate programming or 
from the use of SVT discriminators remains poorly understood. This analysis aims to 
better understand the individual contributions of these two strategies in reducing overall 
inappropriate therapies. 
Methods 
Patients and Procedures 
The PainFree SST trial has been previously described.
7, 8
 In brief, PainFree SST 
was a global, prospective, multicenter trial of patients undergoing de-novo or 
 














replacement implantation (based on current clinical practice guidelines) of an ICD or 
cardiac resynchronization defibrillator (CRT-D) with SST (ClinicalTrials.gov ID: 
NCT00982397). All detected episodes with at least 16 beats in the ventricular detection 
zones and stored with electrograms (EGMs), including ventricular arrhythmias, non-
sustained ventricular tachycardia (NSVT) and SVT, were adjudicated by an independent 
physician episode adjudication committee (EAC).
8
 The ethics committee or IRB at each 
participating institution approved the study protocol and all subjects provided written 
informed consent. 
Device Programming 
Tachyarrhythmia detection and therapies were pre-specified by the study protocol 
to include a VF zone with number of intervals to detect (NID) at 30/40 for primary 
prevention patients and recommended detection interval of 320 msec. Secondary 
prevention patients were randomized between NID 18/24 and 30/40.
10
 No VT or fast VT 
(FVT) zone was recommended for primary prevention patients and programmed per 
physician discretion for secondary prevention patients. Additional specified programming 
in both groups included ATP therapy delivered during charging in the VF zone, and SVT 
discriminators on for a median ventricular interval ≥260ms. Deviations to these 




Given the homogeneity in the way patients were programmed, computer-based 
simulations were performed to determine what the outcome (i.e., therapy delivered or 
withheld) for a given arrhythmia would have been if certain programming features were 
 














activated or deactivated. The scenarios are shown in Supplemental Table 1 and included 
(1) turning off all SVT and ventricular oversensing (VOS) discriminators, (2) having 
SVT/VOS discriminators off in the setting of delayed high-rate detection, and (3) having 
only pre-SmartShock Technology™ discriminators on. Figure 1 illustrates simulation 
scenarios (1) and (2). Panel A is the original AF episode with detection withheld by the 
SST algorithms. In scenario 1, this episode would have been inappropriately detected and 
treated. The episode would not have been detected in scenario 2. Incidence of ICD 
therapies was estimated using Cumulative Incidence Functions treating death as a 
competing risk. Cox proportional hazards regression was used to estimate the hazard ratio 
(HR) for incidence of therapy between simulated scenarios and actual observed therapy 
incidence, accounting for within-patient correlation by the use of a robust covariance 
estimated by the Generalized Estimating Equations (GEE) approach.
11
 GEE was also 
used in context of logistic regression to estimate success of first ATP therapy. 
Results 
Among 2,770 patients (single-chamber [27%], dual-chamber [34%], and CRT 
[39%] defibrillators; 33% replacements or upgrades), 2,599 had device programming 
information available for analysis. Patient characteristics were similar to previously 
published ICD studies (Table 1) and patients were followed for 22±9 months. VF 
detection was programmed on in 2,591 patients (99.7%). The NID was programmed to 
30/40 for 1,693 primary prevention patients (96%) and 387 secondary prevention patients 
(48%). In most of the remaining patients, the NID was programmed to 18/24 (69 primary 
prevention patients [4%] and 422 secondary prevention patients [52%]). VT detection 
and therapies were programmed on in 62% of patients with a median detection rate of 
 














350ms (primary prevention: 57%, median rate: 340ms; secondary prevention: 72%, 
median rate: 360ms). SmartShock Technology™ was programmed on in 96% of patients. 
The SVT limit was programmed to the nominal value of 260ms in 98% of the patients 
(Table 2).  
The EAC adjudicated all 9,660 episodes with available EGMs and with at least 16 
beats in the programmed detection zones. Table 3 and Figure 2 present how the device 
classified the episodes in relation to the adjudicated true rhythm. For 804 episodes, one or 
more shocks were delivered. In total, 115 episodes had inappropriate shocks for an 
inappropriate shock rate of 1.8% at 1 year and 3.1% at 2 years post implant. Additionally, 
113 episodes had inappropriate ATP therapy. The incidence of inappropriate therapy was 
2.7% at 1 year and 4.1% at 2 years (Figure 3, blue line). 
Among the 9,660 episodes, 3,282 episodes that met the rate-based detection 
criteria were adjudicated as SVT, T-wave oversensing, or lead noise. Therapy was 
appropriately withheld for 3,054 episodes (93.1%). Only 6.9% received inappropriate 
therapy and only 3.5% received a shock.  
A high percentage of shocks (58.7%) were appropriately caused by monomorphic 
VT; 34.3% of these were faster than 260ms, the nominal SVT Limit, and only 50.8% 
received ATP as first therapy. Overall, there were 3,316 episodes appropriately treated 
with ATP as first therapy. This first ATP therapy was successful for 2,857 episodes 
(86.2%). Restricted to episodes adjudicated as monomorphic VT, first ATP therapy was 
successful for 2,829 (86.5%) out of 3,270 episodes that received ATP as first therapy. 
 














Corrected for multiple episodes per patient using GEE, first ATP therapy success was 
82.5% (95% confidence interval [CI]: 79.5%-85.2%).  
Since 96% of patients had SST discriminators on, we performed computer-
simulated arrhythmia detection as if SST was deactivated across all 3,282 SVT episodes 
to determine if therapy would have been delivered. The worst-case inappropriate therapy 
rate was simulated by assuming therapy delivery at the moment of detection for all 3,282 
episodes – corresponding to programming all SVT/VOS discriminators off with all other 
detection settings including rate and duration programming unchanged (see Table 2). In 
total, 553 patients would have had one or more inappropriate therapies and the incidence 
would have been 17.6% at 1 year and 22.9% at 2 years (Figure 3, red line). Compared to 
the observed rate, the increase is 524% (HR = 6.24, CI: 5.20-7.49, p<0.0001). A second 
scenario that was simulated involved having SVT/VOS discriminators off but uniformly 
setting all detection parameters to mimic delayed high-rate detection where only a VF 
zone requiring 30/40 beats to be faster than 320ms. This resulted in 480 SVT episodes 
among 158 patients receiving therapy. The incidence rate of inappropriate therapy would 
have been 4.4% at 1 year and 6.4% at 2 years (Figure 3, green line). Compared to the 
observed rate, the increase is 63% (HR = 1.63, CI: 1.44-1.85, p<0.0001). Simulating 
these same detection parameters of only a VF zone requiring 30/40 beats to be faster than 
320ms, but with SVT/VOS discriminators on, the incidence rate of inappropriate therapy 
would have been 2.2% at 1 year and 3.3% at 2 years (Figure 3, black line; HR=0.814, CI: 
0.740-0.895, p<0.0001). 
Atrial fibrillation (AF) was the most common cause of inappropriate therapies and 
PainFree SST included 818 patients (30%) with a history of AF. Excluding these patients, 
 














the observed incidence of inappropriate therapy was 2.0% at 1 year and 3.2% at 2 years. 
With delayed high-rate detection, the incidence would have been 3.8% at 1 year and 
5.6% at 2 years, which is an increase of 81% (HR=1.81, CI: 1.51-2.17, p<0.0001). 
The third simulation scenario involved having delayed high-rate detection with 
only pre- SST discrimination. Dual chamber discrimination include PR Logic, onset and 
stability without wavelet. Single chamber discrimination included wavelet, onset and 
stability. All devices used SVT Limit=320 ms. Lead noise and TWOS discriminators 
were excluded from all devices. The incidence of inappropriate therapy would have been 
4.2% at 1 year and 6.1% at 2 years. 
In terms of VT zone programming, 59% of dual chamber patients had a VT zone 
programmed on with shocks (median VT detection interval of 340ms and 350ms for 
single and dual chamber, respectively). Interestingly, there was no difference in the 
inappropriate shock rate between those with VT zone on vs off
8
, suggesting a role of the 
SST discriminators in providing substantial shock reduction benefit. 
Discussion 
Our aim was to examine the incremental benefit of SVT discriminators beyond 
only delayed high rate programming and the benefit of each component of the algorithm 
that contribute to overall reduction in inappropriate therapies that were observed in the 
PainFree SST trial. This analysis has several important findings: (1) the use of SVT and 
VOS discriminators combined with real-world programming results in a low rate of 
inappropriate ICD therapies among primary and secondary prevention ICD recipients; (2) 
with SST discriminators programmed off, but rate and duration unchanged in these 
 














patients, the inappropriate ICD therapy rate would have increased by 524%; (3) with 
sustained high rate programming and SST discriminators programmed off, the 
inappropriate ICD therapy rate would have increased by 63%; and (4) combined use of 
SVT and VOS discriminators with sustained high rate programming would have 
incrementally decreased the inappropriate ICD therapy rate by 18.6%. Detailed analysis 
of the specific rhythm outcomes and several post hoc simulations of different 
programming scenarios demonstrate that these low inappropriate shock rates could not be 
achieved without the use of these new discriminators. While AF remained the primary 
cause of inappropriate shocks, the SST discriminators were 84% specific for identifying 
AF and accounted for a substantial part of the difference between discriminators on vs. 
off. Although we focused primarily on the reduction in inappropriate therapy, it is worth 
noting that ATP provided substantial benefit in reducing unnecessary shocks for 
monomorphic VT. Of 3,497 episodes of monomorphic VT receiving therapy, ATP was 
associated with the termination of 2,994 (89.1%) episodes.  
In a comprehensive review of studies over the past 15 years, 6.4% of single 
chamber ICD patients had received an inappropriate shock at 12 months.
9
 The PainFree 
SST trial stands out among the trials included in this review as having an unusually low 
inappropriate shock rate in spite of having broad inclusion criteria allowing patients with 
AF and device replacements to be enrolled. These results suggest that the SST 
discriminators played an important role in combination with modern programming 
practices. In general, rate programming in the PainFree SST trial was slower than 
guidelines in part because secondary prevention patients were included, but also due to 
physician discretion. While exercising physician discretion deviates from what would be 
 














considered state of the art programming, it does reflect real world practice when real 
patients are being treated. Among primary prevention patients, 58.6% had a VT zone 
programmed with shock therapies. In spite of this, patients with VT shock programmed 
on had a comparable inappropriate shock rate to that of patients without VT shocks 
primarily because of the SVT discriminators. How well these findings apply to other 
proprietary discriminator algorithms is unclear given that direct comparisons of different 
algorithms are rarely performed. In one such study, algorithms from two device 
manufacturers were compared in a randomized trial demonstrating superiority of one 
over another.
12
 By the time the study was completed and results reported, the competing 
algorithms had been modified. Hence, caution should be exercised when generalizing the 
findings of this study to other types of discriminators. Perhaps what is more important is 
the recent HRS statement highlighting the differences between device manufacturers and 
to avoid generalizing results from one manufacturer’s device to another.
6
 This 
accentuates the need for having manufacturer-specific studies such as this one so that 




While SST has resulted in significant improvements in the rates of inappropriate 
therapies, there is still room for improvement. Enhancements made to improve specificity 
must be balanced by potential compromises on safety as measured by delayed detection 
or loss of consciousness. These were reported in the primary results manuscript of the 
PainFree SST trial.
8
 Detection sensitivity was 98.8%. As seen in table 3 there were 2 
polymorphic rhythms for which detection was withheld by SVT/VOS discriminators. In 
 














addition, there were 17 additional episodes of polymorphic rhythms with delayed 




Several limitations were present that may affect the ability to apply these findings 
to a larger population. First, this was not an interventional trial and the impact of SVT 
discriminators being turned off was assessed using computer-based simulations. 
However, these methodologies have been successfully used in prior studies.
13
 Second, the 
simulations did not factor in a delay that often would result from the ICD capacitor 
charging. We have assumed that with modern ATP programming (including during 
charge) therapy is delivered at time of detection. Additionally, we analyzed not just 
shocks but all types of therapy including ATP. The timing of ATP delivery would not 
have been affected by the lack of having a capacitor delay. Third, the stored RR intervals 
that were the basis for our simulation often do not cover the full duration of ongoing SVT 
episodes. The simulation of delayed high rate detection settings may therefore have 
underestimated the number of episodes that would have received therapy. There were at 
least 977 episodes that had no simulated therapy but where the available interval data was 
truncated. Lastly, the PainFree SST study was a prospective observation study for the 
primary prevention patients and a randomized study for the secondary patients. All of the 
potential biases associated with the primary prevention prospective arm of the study 



















The presence of SVT and VOS discriminators in the setting of modern day real-
world ICD programming plays a significant role in reducing current rates of inappropriate 
ICD therapies. In a simulated scenario without SVT and VOS discriminators on, the 
incidence of inappropriate therapies would have increased by 524% when compared to 
the actual study findings.  
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Figure 1. Simulation scenarios. Panel A is an atrial fibrillation (AF) episode recorded 
during the PainFree SST trial. The patient was a 65 year old male with a history of AF, 
coronary artery disease, hypertension, and myocardial infarction. The AF detection rule 
of PR Logic, a component of the SST algorithms, begins withholding detection when the 
VT Count reaches VTNID (= 16) indicated by AF in the decision channel as shown at the 
bottom right in the panel. Panel B is the same AF episode edited to provide a visual of the 
first simulation in which the SVT discriminators are off and other detection settings are 
unchanged. In this case, the episode would be detected when the VT Count reaches 
VTNID, and ATP therapy initiated as shown in the panel. Panel C illustrates the second 
simulation method. In this case, the same AF episode from panel A is simulated with 
SVT discriminators off and delayed high rate detection settings used. In this case, none of 
the beats are faster than the detection interval of 320 ms so the counter will not increment 



































Figure 2. Episode detection versus adjudicated rhythm. This includes all episodes 
with stored EGMs and at least 16 beats in the programmed detection zones. Detection 


















Figure 3. Actual vs simulated inappropriate therapy rates. The figure includes all 
episodes with stored EGMs that met programmed detection criteria in the VT or VF 
zones, and either received inappropriate therapy or were appropriately classified as SVT 
by the device. The blue line shows actual therapy delivered with SVT discriminators on 
and detection criteria as programmed (PainFree SST study results). The red line is the 
simulated therapy that would have been delivered had the SVT discriminators been 
turned off and detection criteria as programmed. The green line shows the simulated 
therapy had SVT discriminators been turned off and programmed detection changed to 
having only a VF zone with NID 30/40 detection and a 320ms detection rate. The black 
line shows the simulated therapy had SVT discriminators been turned on and 
programmed detection changed to having only a VF zone with NID 30/40 detection and a 
320ms detection rate, which results in a 18.6% reduction of the inappropriate therapy rate 


















Table 1: Patient characteristics 
Patient characteristics All patients 
(N = 2770) 
Demographics and Clinical Presentation  
Male (N, %) 2200 (79%) 
Age (years) 65 ± 12 
LVEF (%) 32 ± 13 
QRS duration (msec) 126 ± 33 
Secondary prevention (N, %) 847 (31%) 
NYHA class (N,%)  
I 419 (15%) 
II 1104 (40%) 
III 853 (31%) 
IV 38 (1%) 
No Heart Failure 354 (13%) 
  
History (N, %)  
Ischemic cardiomyopathy 1206 (44%) 
Coronary artery disease 1745 (63%) 
Previous device, any 923 (33%) 
  
Arrhythmias and Conduction Defects (N, 
%) 
 
Atrial fibrillation 818 (30%) 
Non-sustained Ventricular Tachycardia 588 (21%) 
Sustained monomorphic Ventricular 
Tachycardia 
281 (10%) 
AV block 404 (15%) 
Left bundle branch block 699 (25%) 
Right bundle branch block 215 (8%) 
 














Patient characteristics All patients 
(N = 2770) 
  
Device (N, %)  
CRT-D 1071 (39%) 
Dual-chamber ICD 948 (34%) 
Single-chamber ICD 751 (27%) 
AV, Atrioventricular; CRT-D, Cardiac Resynchronization Therapy Defibrillator; LVEF, Left Ventricular Ejection Fraction; 
NYHA, New York Heart Association; ICD, Implantable Cardioverter Defibrillator 
Table 2: Detection programming 
Detection programming 
All patients 















     
No programming details 
available 
171 (6.2%) 138 (7.2%) 31 (3.7%) < 
0.001 
     
Detection programming     
VF detection On 2591 (99.7%) 1773 (99.7%) 814 (99.8%) 1.00 
VF NID
3
     
18 / 24 491 (19.0%) 69 (3.9%) 422 (51.8%)  
30 / 40 2084 (80.4%) 1693 (95.5%) 387 (47.5%)  
Other 16 (0.6%) 11 (0.6%) 5 (0.6%)  
VF detection interval (ms)
3
 304 ± 17 303 ± 17 304 ± 18 0.31 
     
FVT detection zone enabled 880 (33.9%) 538 (30.2%) 341 (41.8%) < 
0.0001 
     
VT detection On 1636 (62.9%) 1042 (58.6%) 592 (72.5%) < 
0.0001 
 

































 21 ± 5 21 ± 5 21 ± 6 0.86 
VT interval (ms)
3
 357 ± 30 350 ± 21 370 ± 38 < 
0.0001 
Any VT therapy 1610 (61.9%) 1022 (57.4%) 586 (71.8%) < 
0.0001 
Any VT shock therapy 1545 (59.4%) 996 (56.0%) 547 (67.0%) < 
0.0001 
     
SVT discrimination enabled 
(N,%) 
    
AF rejection rule enabled
4
 1831 (97.1%) 1284 (97.6%) 545 (95.8%) 0.036 




1831 (97.1%) 1284 (97.6%) 545 (95.8%) 0.036 
Wavelet rejection rule enabled 2531 (97.4%) 1742 (97.9%) 785 (96.2%) 0.024 
All enabled 2485 (95.6%) 1713 (96.3%) 768 (94.1%) 0.017 
SVT limit programmed nominal 
(260 ms) 
2544 (97.9%) 1740 (97.8%) 800 (98.0%) 0.77 
CRT-D, Cardiac Resynchronization Therapy Defibrillator; FVT, Fast Ventricular Tachycardia; ms, millisecond; NID, 
Number of Intervals to Detect; SVT, Supraventricular Tachycardia; VF, Ventricular Fibrillation; VT, Ventricular 
Tachycardia 
1
 Indication is missing for 6 patients 
2
 Tests are Student's t-test for continuous and Fisher's exact test for categorical variables 
3
 Includes only the cases where the respective detection zone is enabled 
4
 Not available in Single-Chamber devices 
  
 














Table 3: Episode rhythm vs adjudicated rhythm. This includes all 9,660 episodes 
with stored EGM and at least 16 beats in the programmed detection zones. There 
were 10 true VT/VF episodes that received an inappropriate shock after 
spontaneous termination and 4 SVT/VOS episodes that received an appropriate 
shock after inappropriate ATP. The 3,282 SVT/VOS episodes that met the rate-
based detection criteria are the episodes with inappropriate therapy in the top two 




(N = 379) 
Monomorphic 
VT 
(N = 4389) 
NSVT 
(N = 645) 
SVT 
(N = 4014) 
Lead Noise 
(N = 105) 
TWOS 
(N = 128) 
Shocked 220 (58.0%) 475 (10.8%) 0 (0.0%) 81 (2.0%) 23 (21.9%) 5 (3.9%) 
ATP only 30 (7.9%) 3031 (69.1%) 2 (0.3%) 110 (2.7%) 0 (0.0%) 0 (0.0%) 
VT monitor zone 8 (2.1%) 619 (14.1%) 59 (9.1%) 710 (17.7%) 0 (0.0%) 27 (21.1%) 
Therapy aborted 64 (16.9%) 21 (0.5%) 14 (2.2%) 24 (0.6%) 44 (41.9%) 4 (3.1%) 
Delayed detection 17 (4.5%) 65 (1.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Non-sustained 38 (10.0%) 132 (3.0%) 462 (71.6%) 149 (3.7%) 2 (1.9%) 14 (10.9%) 
Detection withheld: Onset/Stability 1 (0.3%) 10 (0.2%) 43 (6.7%) 95 (2.4%) 0 (0.0%) 0 (0.0%) 
Detection withheld: PR Logic 1 (0.3%) 21 (0.5%) 15 (2.3%) 1595 (39.7%) 0 (0.0%) 0 (0.0%) 
Detection withheld: Wavelet 0 (0.0%) 15 (0.3%) 17 (2.6%) 1250 (31.1%) 0 (0.0%) 21 (16.4%) 
Detection withheld: Lead Noise 0 (0.0%) 0 (0.0%) 33 (5.1%) 0 (0.0%) 36 (34.3%) 7 (5.5%) 
Detection withheld: TWOS 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 50 (39.1%) 
ATP, Antitachycardia Pacing; NSVT, Non-Sustained Ventricular Tachycardia; SVT, Supraventricular Tachycardia; 
TWOS, T-wave Oversensing; VF, Ventricular Fibrillation; VT, Ventricular Tachycardia 
 
